EP0116538A1 - Method of treating pruritis and composition therefor - Google Patents
Method of treating pruritis and composition thereforInfo
- Publication number
- EP0116538A1 EP0116538A1 EP82902866A EP82902866A EP0116538A1 EP 0116538 A1 EP0116538 A1 EP 0116538A1 EP 82902866 A EP82902866 A EP 82902866A EP 82902866 A EP82902866 A EP 82902866A EP 0116538 A1 EP0116538 A1 EP 0116538A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- naloxone
- pharmaceutically acceptable
- acceptable salt
- naltrexone
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Definitions
- the present invention relates to a composition for relieving pruritis.
- pruritis Itching or pruritis is a common dermatologi ⁇ symptom. ⁇ p ne causes of pruritis are complex and poorly understood. The best understood mechanism of itching is the release of histamine in the skin leading to urticarial wheals-and intense itching. Such itching has traditionally been relieved by antihistamines. While antihistamine therapy is often effective, the sedation and drowsiness produced by antihistaminic agents limits their effectiveness.
- Naloxone is a narcotic antagonist which is not known to cause physical or psychological dependence and which exhibits essentially no pharmacological activity in non-addicts. Naloxone is normally given by injection to addicts to assist them in narcotic with ⁇ drawal and"sometimes is administered to post operative patients for partial reversal of narcotic depression following the use of narcotics during surgery. It has been found surprisingly that topical " applications of Naloxone are useful in alleviating severe itching in various conditions.
- the present invention provides a method for relieving severe itching in patients in need of such treatment, said method comprising topically administer ⁇ ing a therapeutically effective amount of Naloxone or a pharmaceutically acceptable salt thereof or Naltrex- one to a patient in need of such treatment.
- Naloxone hydrochloride is commercially avail- able from Endo Laboratories, Inc., a subsidiary of the DuPont Company, 1000 Stewart Avenue, Garden City, New York 11530.
- the preparation of Naloxone is disclosed in U.S. Patent No. 3,254,088.
- pharmaceutically acceptable salts refers to the physiologically acceptable acid addition salts of Naloxone such as the hydrochloride, hydrobromide, hydroiodide, acetate, valerate, oleate, etc.
- Liquid dosage forms for topical administra- tion includes acceptable emulsions, solutions and sus ⁇ pensions containing volatile diluents commonly used in the art, such as alcohol, glycol and the like. Besides such diluents, topically applied compositions may also include wetting agents, emulsifying and suspending agents.
- & JREA the form of a pharmaceutically acceptable salt such as the hydrochloride and pharmaceutically acceptable chemical derivatives thereof such as Naltrexone which is the n-methyl cyclopropyl derivative are incorporated into solutions, lotions, creams, and ointments for topical application in concentrations of from 0.01 to about 5 percent by weight. These topical products are applied to the skin 1 to 8 times daily. The relief experienced by those receiving the topical application was prompt although temporary.
- Naloxone hydrochloride 1 percent by weight Naloxone hydrochloride was incorporated into a solution composed of 70 percent by volume ethyl alcohol and 30 percent by volume propylene glycol and applied 6 times daily to 2 mosquito bites of less than 24 hours duration on an 11 year-old male. This child noted relief from his itching within 10 minutes of each application and the relief lasted 2-4 hours.
- Eucerin (R.T.M) cream is a synthetic lanolin containing cream produced by Beiersdorf, Inc. of South Norwalk, Conneticut 06854. This was the first topical product the patient used that provided him with any significant relief from his itching.
- Naloxone hydrochloride 5% by weight Naloxone hydrochloride was in ⁇ corporated into an ointment and applied 4 times daily for two days to a small eczematous patch on the left hand of a 38 hear-old male. Itching was dramatically reduced by each application of the test ointment.
Abstract
Traitement topique pour soigner le prurit suivant lequel de la Naloxone, un sel pharmaceutiquement acceptable d'un dérivé chimique pharmaceutiquement acceptable, est utilisée topiquement dans une lotion, une solution, une crème ou une pommade.Topical treatment to treat pruritus according to which Naloxone, a pharmaceutically acceptable salt of a pharmaceutically acceptable chemical derivative, is used topically in a lotion, a solution, a cream or an ointment.
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1982/001152 WO1984000889A1 (en) | 1982-08-25 | 1982-08-25 | Method of treating pruritis and composition therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0116538A1 true EP0116538A1 (en) | 1984-08-29 |
EP0116538A4 EP0116538A4 (en) | 1985-04-25 |
Family
ID=22168155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19820902866 Withdrawn EP0116538A4 (en) | 1982-08-25 | 1982-08-25 | Method of treating pruritis and composition therefor. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0116538A4 (en) |
JP (1) | JPS59501712A (en) |
AU (1) | AU8952282A (en) |
DK (1) | DK206584D0 (en) |
WO (1) | WO1984000889A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU201675B (en) * | 1983-08-26 | 1990-12-28 | Ivan Balkanyi | Process for producing oral pharmaceutical compositions with unappetizing effect |
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
US5096715A (en) * | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
GB9725114D0 (en) * | 1997-11-28 | 1998-01-28 | Pfizer Ltd | Treatment of pruritus |
CA2561509C (en) * | 2004-03-30 | 2012-08-28 | Toray Industries, Inc. | Anti-itching agent |
CN101426481B (en) * | 2006-04-21 | 2012-12-05 | 帝斯曼知识产权资产管理有限公司 | Use of opioid receptor antagonists |
US20090093509A1 (en) * | 2007-10-08 | 2009-04-09 | Tahir Nazir | Methods and Compositions for the Treatment of Pruritus |
US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
SG11202100580UA (en) | 2018-07-23 | 2021-02-25 | Trevi Therapeutics Inc | Treatment of chronic cough, breathlessness and dyspnea |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773955A (en) * | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US4181726A (en) * | 1978-11-16 | 1980-01-01 | Bernstein Joel E | Method of alleviating pruritis |
-
1982
- 1982-08-25 AU AU89522/82A patent/AU8952282A/en not_active Abandoned
- 1982-08-25 WO PCT/US1982/001152 patent/WO1984000889A1/en not_active Application Discontinuation
- 1982-08-25 JP JP50294282A patent/JPS59501712A/en active Pending
- 1982-08-25 EP EP19820902866 patent/EP0116538A4/en not_active Withdrawn
-
1984
- 1984-04-25 DK DK2065/84A patent/DK206584D0/en not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
No relevant documents have been disclosed. * |
See also references of WO8400889A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0116538A4 (en) | 1985-04-25 |
DK206584A (en) | 1984-04-25 |
WO1984000889A1 (en) | 1984-03-15 |
DK206584D0 (en) | 1984-04-25 |
AU8952282A (en) | 1984-03-29 |
JPS59501712A (en) | 1984-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4416886A (en) | Method of treating pruritis and composition therefor | |
DE69737592T2 (en) | MEDIUM AGAINST JUCKREIZ | |
CA1254582A (en) | PHENYL .alpha.-ACYLOXYACETAMIDE DERIVATIVES AND THEIR THERAPEUTIC USE | |
DK159757B (en) | APPLICATION OF NAPHTHALENDER DERIVATIVES FOR THE PREPARATION OF A MEDICINE FOR TREATMENT OR PROPHYLACY OF INFLAMMATION BY TOPIC ADMINISTRATION AND PHARMACEUTICAL PREPARATION FOR TOPICAL USE CONTAINING NAPHTHREEN | |
JP5613417B2 (en) | A therapeutic agent for improving skin properties comprising a morphinan derivative or a pharmacologically acceptable acid addition salt thereof as an active ingredient | |
JPS6241688B2 (en) | ||
US5866143A (en) | Topical application of opioid drugs such as morphine for relief of itching and skin disease | |
Paterson et al. | Drug therapy of glaucoma. | |
EP0116538A1 (en) | Method of treating pruritis and composition therefor | |
US5187177A (en) | Method and a pharmaceutical preparation for treating pain | |
CA1177406A (en) | Composition for treating pruritis | |
US4181726A (en) | Method of alleviating pruritis | |
US4946848A (en) | Method of treating pruritus with nalmefene and clonidine | |
US4923875A (en) | Method for treatment of mast cell-mediated dermatologic disorders | |
US4315024A (en) | Compositions and method for treating red eye | |
US5128375A (en) | Keloid treating agent | |
LV12918B (en) | Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade | |
CA1189794A (en) | Composition for treating pruritis | |
US4829068A (en) | Treatment of disorders of the gastro-intestinal tract | |
DE60024408T2 (en) | USE OF TRICYCLIC ANTIDEPRESSIVA FOR THE TREATMENT OF HEADACHE | |
RU2063753C1 (en) | Method for treating extrapyramidal syndrome in the cases of acute poisoning with haloperidol | |
RU2426540C1 (en) | Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition | |
US6693100B1 (en) | Pharmaceutical compositions for treating psoriasis | |
RU2136309C1 (en) | Method of treatment of huntington's chorea | |
DE60210804T2 (en) | USE OF PROPIONYL L-CARNITINE OR ITS PHARMACOLOGICALLY ACCEPTABLE SALTS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF LA PEYRONIE'S DISEASE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19840914 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
17Q | First examination report despatched |
Effective date: 19860624 |
|
18D | Application deemed to be withdrawn |
Effective date: 19860304 |
|
D17Q | First examination report despatched (deleted) |